NCSI is developing a portfolio of percutaneous delivery systems for implanting the atrioventricular valved stent. The most advanced delivery systems are the trans jugular (animation below) and trans atrial (image below). There is an on-going effort to develop a trans femoral delivery system.
Trans-jugular Approach: Animation
Trans-atrial Approach: Image
GATE™ System Overview
Ventricular View (ØRV)
The GATE™ System is intended to treat functional tricuspid regurgitation (FTR)/tricuspid insufficiency by replacing the function of a patient’s dysfunctional native tricuspid valve with a bio-prosthetic atrioventricular valved stent (AVS). The AVS is designed to restore valve function in patients presenting with FTR/tricuspid insufficiency without the need for conventional, open-heart surgery.
The GATE™ System is comprised of an Atrioventricular Valved Stent (AVS), delivery catheter and related accessories. The AVS is being developed in a range of sizes, including Ø40mm, Ø44mm, Ø48mm, and Ø52mm, with a maximum profile height of 23mm.
Atrial View (ØRA)
The AVS is of tri-leaflet design and includes patented partially dehydrated tissue technology, a self-expanding Nitinol stent and special fabric to encourage fibrous ingrowth of biological material to aid in inter-chamber sealing of the device. The design of the AVS is intended to capture the native annulus and leaflets of the dysfunctional tricuspid valve.